Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 12/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.59 |
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.53 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.53 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4520823 | 1.00 | KDM4A (0.59) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL145724 | 0.97 | — | — | |
| Water SCHEMBL28287600 | 0.95 | KDM4A (0.53) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| Methane SCHEMBL28698626 | 0.95 | KDM4A (0.53) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| Hydrochloric Acid SCHEMBL6647561 | 0.92 | KDM4A (0.66) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL27684562 | 0.92 | KDM4A (0.52) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| Hydrochloric Acid SCHEMBL8815361 | 0.92 | KDM4A (0.52) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| Hydrochloric Acid SCHEMBL247487 | 0.90 | KDM4A (0.69) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL247791 | 0.90 | KDM4A (0.64) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL3402761 | 0.87 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118652188-A | Synthesis method of Dlin-MC3-DMA finished product | 艾伟拓(江苏)医药科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118359515-A | Betaine type zwitterionic lipid and preparation method thereof | 大连理工大学 | 2024-07-19 | — | — | CN | claimed |
| CN-115260315-A | Modification method of cellulose, betaine amphoteric cellulose and preparation method and application thereof | 深圳华源再生医学有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-8940793-B2 | 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease | JSC GRINDEKS (LV) | 2015-01-27 | — | — | US | claimed |
| US-20140107202-A1 | 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease | JSC GRINDEKS (LV) | 2014-04-17 | — | — | US | claimed |
| EP-2702037-A1 | 4-[(HALOALKYL)(DIMETHYL)AMMONIO]BUTANOATES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISEASE | Grindeks, A Joint Stock Company (LV) | 2014-03-05 | — | — | EP | claimed |
| WO-2012146737-A1 | 4-[(HALOALKYL)(DIMETHYL)AMMONIO]BUTANOATES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISEASE | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2012-11-01 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-05-26 | — | — | US | disclosed |
| EP-4495237-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2026-05-13 | — | — | EP | disclosed |
| US-12622878-B2 | Cationic lipid having cystine skeleton | NOF CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| WO-2026089243-A1 | NOVEL IONIZABLE STEROL DERIVATIVE AND LIPID NANOPARTICLE COMPOSITION COMPRISING SAME | 재단법인 대구경북첨단의료산업진흥재단 | 2026-04-30 | — | — | WO | disclosed |
| US-20260115139-A1 | Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NANOVATION THERAPEUTICS INC. (CA) | 2026-04-30 | — | — | US | disclosed |
| EP-4727915-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2026-04-22 | — | — | EP | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
| US-4675341-A | BRAIN INJURIES; PREVENTION OF EDEMA | MERCK & CO., INC. (US) | 1987-06-23 | — | — | US | disclosed |
| EP-0222413-A2 | Novel forskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1987-05-20 | — | — | EP | disclosed |
| US-4624947-A | CALCIUM BINDING AGENT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1986-11-25 | — | — | US | disclosed |
| US-4172943-A | ANALGESICS, TRANQUILIZERS, SEDATIVES, ANTIGLAUCOMA AGENTS | ABBOTT LABORATORIES (US) | 1979-10-30 | — | — | US | disclosed |
| US-4111942-A | ANALGESIC, TRANQUILIZER, SEDATIVE-HYPNOTIC | ABBOTT LABORATORIES (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107202-A1 | 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease | FABP3, HCN3, HCN4 | KDM4A 1032/4885KDM4C 1459/4885KDM5A 1495/4885 |
| US-20260115139-A1 | Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | SLC43A1, SLC7A1, SLC7A5 | KDM4A 4343/4885KDM4C 4429/4885KDM5A 4600/4885 |
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | NSUN2, NSUN3, RNMT | KDM4A 2027/4885KDM4C 1218/4885KDM5A 2673/4885 |
| US-12622878-B2 | Cationic lipid having cystine skeleton | ABCB7, ABCB4, SLC27A1 | KDM4A 2372/4885KDM4C 2660/4885KDM5A 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.